Figure 3 | Leukemia

Figure 3

From: SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

Figure 3

SB1518 induces apoptosis, cell cycle arrest and inhibition of proliferation in cancer cells. (a) SET-2 and Karpas 1106P cells were treated for 16 h with SB1518, and caspase-3/7 activity was determined. (b) SET-2 and Karpas 1106P cells were treated for 24 h with SB1518 at 1 × and 3 × IC50 and the cell cycle analysis was performed using propidium-iodine staining followed by flow cytometric measurement. (c) To determine the cell proliferation IC50 values, cells were treated for 48 h with various concentrations of SB1518 and their viability tested with CellTiter-Glo Assay (Promega). The mean IC50 results were calculated from four independent experiments. The error bars on bar graph denote s.d.'s. **For SNU-387 and SNU-475, n=2 and the error bars denote data spread.

Back to article page